the aid library

LIST OPTIONS

Filter

8560

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Download (153)

View PDF (178)

Краткое руководство по видеосопровождению при лечении туберкулеза

World Health Organization WHO, Regional Office of Europe (2020) C_WHO

Quick guide to video-supported treatment of tuberculosis (2020). Despite being a curable and preventable disease, tuberculosis (TB) remains as one of the major challenges for health systems, globally. Every year, TB affects more than 10 million people and kills more than 1.4 million people. WHO’... more

Download (1774)

View PDF (2113)

Study on the Gendered Impacts of Ebola in Liberia (February 2015)

Leena Kotilainen Finn Church Aid (2015)

This study examines the gendered impacts of the Ebola virus disease (EVD) in Liberia in the largest outbreak of EVD ever recorded. The findings are based on an extensive two-week desk study and one-week participatory field study conducted in January 2015 in the cities of Monrovia and Buchanan in Lib... more

Download (3986)

View PDF (5615)

Kenya Essential Medicines List 2019
recommended

Ministry of Health, Kenya (2019) C1

The Kenya Essential Medicines List 2019 is an indispensable guide to the medicines recommended for the management of common conditions in Kenya. It is primarily directed at health care providers and medicines supply managers in the public and non-public health sectors. It should be used together wit... more

Download (227)

View PDF (197)

Global oral health status report: towards universal health coverage for oral health by 2030: regional summary of the Western Pacific Region

World Health Organisation (WHO) (2023) C_WHO

This regional summary draws on the WHO Global oral health status report (2), published in 2022, which provides a comprehensive overview of the global oral disease burden, the global health importance of oral health and the impact of oral diseases over the life course. The summary focuses on the ... more

Containing Hemorrhagic Fever Epidemic, The Ebola Experience in Uganda (October 2000 – January 2001)

Lamunu M, Lutwama J.J, Kamugisha J; et al. (2002)

A paper presented at the 10th International Congress on Infectious Disease, Singapore

Download (1861)

View PDF (2567)

HPV Vaccine Communication: Special considerations for a unique vaccine

World Health Organization WHO (2013) C_WHO

A lack of knowledge about the threat of vaccine-preventable diseases, risks and benefits of vaccines, mistrust of government and health workers, poor service delivery and alternative health or religious beliefs play a role in lower uptake of some vaccines. These challenges underscore the importance ... more

Download (696)

View PDF (2306)

Travel and transport risk assessment: Interim guidance for public health authorities and the transport sector

World Health Organization WHO (2014)

This guidance document includes background information on Ebola virus disease, Ebola emergency committee recommendations, risks for different groups, and information for travellers from and to affected countries.

India: Leprosy Training Manual For Health Workers and Supervisors

National Leprosy Eradication Programme; National Health Mission; Ministry of Health & Social Welfare India (2014) C1

Course contents: What is Leprosy? Leprosy is a disease caused by a micro-organism called Mycobacterium leprae

Download (129)

View PDF (162)

WHO Bangladesh Country Cooperation Strategy: 2020–2024

World Health Organization (WHO), Regional Office for South-East Asia (2022) C_WHO

Notable progress has also been made on other key health indicators such as reducing maternal, infant and child deaths and malnutrition, increasing immunization coverage, eliminating infectious diseases such as polio and reducing the incidence of malaria, tuberculosis and diarrhoeal diseases. But ... more

Download (932)

View PDF (1267)

Ghana: Public Health Act

Government of Ghana (2012) C1

Act 851 | AN ACT to revise and consolidate the law relating to public health to prevent disease, promote, safeguard, maintain and protect the health of humans and animals and to provide for related matters.

Download (675)

View PDF (2071)

Communication Risk in Public Health Emergencies
recommended

World Health Organization (WHO) (2018) C_WHO

A WHO Guideline for Emergency Risk Communication (ERC) policy and practice. Recent public health emergencies, such as the Ebola virus disease outbreak in West Africa (2014–2015), the emergence of the Zika virus syndrome in 2015–2016 and multi-country yellow fever outbreaks in Africa in 2016, h... more

Download (418)

View PDF (571)

Business case for WHO immunization activities on the African continent 2018-2030

World Health Organization (WHO) (2018) C_WHO

The Global Vaccine Action Plan (GVAP) 2011-2020, endorsed by Member States during the May 2012 World Health Assembly, has set ambitious targets to improve access to immunization and tackle vaccine-preventable diseases. This responsibility has been translated into firm commitments in February 2016, t... more

Download (629)

View PDF (889)

Establishment of PCR laboratory in developing countries, 2nd ed.
recommended

World Health Organization ( WHO), Regional Office for South-East-Asia (2016) C_WHO

Polymerase Chain Reaction (‎PCR)‎ has significantly helped in early diagnosis and commencement of specific interventions for diseases control. It also plays a critical role in understanding the disease epidemiology and unraveling the transmission dynamics of the disease. This manual intends to p... more

Download (313)

View PDF (365)

Sodium intake and iodized salt in the South-East Asia Region

World Health Organization (WHO), Regional Office for South-East Asia (2015) C_WHO

Report of a regional workshop, New Delhi, India, 29–30 September 2014
To reduce the burden of cardiovascular disease and its subsequent problems, the WHO Regional Office for South-East Asia organized a regional workshop on sodium intake and iodized salt for Member States in the South-East Asi... more

Download (397)

View PDF (569)

National Guidelines on TB/HIV Management and Program Collaboration and Implementation Manual, 2nd ed.

Government of the People’s Republic of Bangladesh, Ministry of Health and Family Welfare, Directorate General of Health Services (2016) C1

National Tuberculosis Control Program; Mycobacterial Disease Control National AIDS/STD Program

Download (287)

View PDF (372)

The Socio-Economic Impact of People Living with HIV at the Household Level in Myanmar

Cercone, James; Pinder, Étoile; Pothuis, Michal et al. The Republic of the Union of Myanmar, Ministry of Health and Sports; UNDP (2016) C1

The study collected data on the impact of HIV-related diseases on income, revenues, economic dependency, consumption, education, health, food security, stigma, discrimination, quality of life, and migration. The study also assessed people living with chronic diseases in order to compare the impact o... more

Download (343)

View PDF (590)

Tuberculosis surveillance and monitoring in Europe - 2020 data
recommended

WHO Regional Office for Europe (WHOEurope) and the European Centre for Disease Prevention and Control (ECDC). (2022) C1

TB remains one of the world’s deadliest infectious diseases, second only to COVID-19, and drug-resistant TB strains are still a major concern. In the fight against TB, urgent investment is critical, especially in the context of the ongoing pandemic.

Download (468)

View PDF (381)

WHO Methodology for Point Prevalence Survey on Antibiotic Use in Hospitals

World Health Organization WHO (2019) C_WHO

Version 1.1. The WHO protocol has been adapted to resource-limited settings and builds on existing methodologies from the European Centre for Disease Prevention and Control (ECDC), the Global PPS project from University of Antwerp, the US Centers for Disease Control and Prevention (CDC), and the Med... more

Download (215)

View PDF (285)

The Burden of Mental Disorders in the Region of the Americas

World Health Organization, Pan American Health Organization (2018) C_WHO

This report aims to improve the assessment of mental health needs in the Americas by providing an updated and nuanced picture of: (a) the disability resulting from mental, substance use, and specific neurological disorders, plus self-harm, alone and in combination with premature mortality; (b) the i... more

Kenya Essential Medicines List 2019 recommended

Communication Risk in Public Health Emergencies recommended

Establishment of PCR laboratory in developing countries, 2nd ed. recommended

Tuberculosis surveillance and monitoring in Europe - 2020 data recommended

Kenya Essential Medicines List 2019
recommended

Communication Risk in Public Health Emergencies
recommended

Establishment of PCR laboratory in developing countries, 2nd ed.
recommended

Tuberculosis surveillance and monitoring in Europe - 2020 data
recommended